Antigen News and Research

RSS

Researchers clone T-cell receptor that binds to antigens associated with prostate and breast cancer

Researchers at Uppsala University have cloned a T-cell receptor that binds to an antigen associated with prostate cancer and breast cancer. T cells that have been genetically equipped with this T-cell receptor have the ability to specifically kill prostate and breast cancer cells.

14 Sep 2012

Mayo Clinic receives FDA approval for Choline C 11 Injection to help detect prostate cancer

The U.S. Food and Drug Administration today approved the production and use of Choline C 11 Injection, a Positron Emission Tomography (PET) imaging agent used to help detect recurrent prostate cancer.

13 Sep 2012

Strep throat should be treated with penicillin or amoxicillin: IDSA guidelines

Although people often say they have "strep" throat, most sore throats actually are caused by a virus, not streptococcus bacteria, and shouldn't be treated with antibiotics, suggest guidelines published by the Infectious Diseases Society of America (IDSA). Antibiotics are ineffective against viruses.

11 Sep 2012

Methodist Hospital develops new technology to rapidly detect drug-resistant TB

Technology developed by scientists at The Methodist Hospital Research Institute could halve the time it takes to diagnose tuberculosis infection, and also tell doctors in a day or two whether the bacteria are drug resistant -- a process that currently takes weeks. Initial tests of the device were recently described in Scientific Reports, a Nature online journal.

11 Sep 2012

CSL Biotherapies receives U.S. Government contract to supply pandemic vaccine antigens

CSL Biotherapies, a subsidiary of CSL Limited, one of the world's leading manufacturers of influenza vaccine, announced it has been awarded a contract by the United States (U.S.) Department of Health and Human Services to supply pre-pandemic and pandemic vaccine antigens and related services to the U.S. national stockpile.

11 Sep 2012

Data from Sangamo BioSciences’ SB-728-T Phase 1 clinical programs on HIV/AIDS

Sangamo BioSciences, Inc. announced that data from its Phase 1 clinical programs to develop SB-728-T, a novel therapeutic approach designed to generate a "functional cure" for HIV/AIDS, were presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

11 Sep 2012

Intermittent hormone therapy effective for prostate cancer patients

Intermittent androgen deprivation is as effective as continuous therapy for men with rising prostate-specific antigen levels after primary or salvage radiotherapy, say researchers who believe the break from treatment improves quality of life.

10 Sep 2012

Therapeutic targets for pemphigus vulgaris discovered

Researchers have identified the primary target of the autoantibodies found in the serum of patients with the blistering skin disorder pemphigus vulgaris.

7 Sep 2012

Reduced NF-κB expression linκed to postradiation oral mucosa vulnerability

The fragility of oral mucosa after radiotherapy for oral squamous cell carcinoma may be due to the inhibition of the DNA transcriptor protein nuclear factor κappa-light-chain-enhancer of activated B cells, show study findings.

6 Sep 2012

Baxter commences anti-MIF antibody Phase I trial in malignant solid tumors

Baxter International Inc. today announced that the company has begun dosing patients with malignant solid tumors in a Phase I clinical trial of a monoclonal antibody, representing the company's efforts to extend its oncology portfolio with advanced biological research and development.

From Baxter International Inc. 6 Sep 2012

Study sheds new light on why most bone marrow transplant patients suffer acute GVHD

A team of scientists led by a bone marrow transplant researcher at Fred Hutchinson Cancer Research Center has shed new light on why most bone marrow transplant patients who receive tissue-matched cells from unrelated donors still suffer acute graft-versus-host disease (GVHD).

6 Sep 2012

ImmusanT commences Nexvax2 clinical trials for celiac disease in New Zealand, Australia and the U.S.

ImmusanT announced today that it has initiated clinical trials in New Zealand, Australia and the U.S. to evaluate Nexvax2, the first therapeutic vaccine for patients with celiac disease. Nexvax2 is designed to re-establish patients' tolerance to the toxic effects of gluten, a protein in wheat, barley and rye, and allow them to return to a normal diet.

5 Sep 2012

PRISM technique as accurate as ELISAs in identifying proteins within biological samples

Combining two well-established analytic techniques and adding a twist identifies proteins from blood with as much accuracy and sensitivity as the antibody-based tests used clinically, researchers report this week in Proceedings of the National Academy of Sciences Early Edition online.

4 Sep 2012

Potassium-channel autoimmunity linked to chronic pain

A substantial proportion of patients with voltage-gated potassium channel-complex autoimmunity experience chronic idiopathic pain, although the specific antigenic complex associated with pain remains to be determined, conclude US scientists.

3 Sep 2012

Sophiris announces data from PRX302 transrectal safety study on Benign Prostatic Hyperplasia

Sophiris Bio Inc. today announced data from its transrectal safety study, in which PRX302, the company's drug candidate for the treatment of Benign Prostatic Hyperplasia (BPH or enlarged prostate), was well tolerated through three months following a transrectal injection.

1 Sep 2012

Soligenix’s RiVax induces greater ricin neutralizing antibody levels in humans

Soligenix, Inc., a development stage biopharmaceutical company, announced today the results of a Phase 1B clinical trial of an aluminum hydroxide (Alum) adjuvanted formulation of RiVax, designed to improve the immunogenicity of the vaccine.

31 Aug 2012

Researchers discover new immune response mechanism during infection

Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered a new "first response" mechanism that the immune system uses to respond to infection. The findings challenge the current understanding of immunity and could lead to new strategies for boosting effectiveness of all vaccines. The study, conducted in mice, published online today in the journal Immunity.

31 Aug 2012

Childhood coagulation marker levels distinct from adulthood

Levels of key coagulation markers significantly vary with age in children, research reveals, potentially affecting the diagnosis and treatment of pediatric thrombotic and hemorrhagic disease.

29 Aug 2012

Human Vaccines & Immunotherapeutics Special Focus provides critical view on cancer vaccines

In one of the most comprehensive peer-reviewed discussions on cancer vaccines and immunotherapeutics, a Special Focus in the journal Human Vaccines & Immunotherapeutics provides a critical view on cancer vaccines and a discussion on best approaches for the future.

28 Aug 2012

Research roundup: Who do patients seek for primary care?; Treating kids with antipsychotics

n order to find out what kind of doctor patients were visiting for primary care service, researchers analyzed the frequency in which patients visited generalists and specialists in 1999 and 2007 by using a nationally representative sample of outpatient visits.

26 Aug 2012

Antigen News and Research

Researchers clone T-cell receptor that binds to antigens associated with prostate and breast cancer

Mayo Clinic receives FDA approval for Choline C 11 Injection to help detect prostate cancer

Strep throat should be treated with penicillin or amoxicillin: IDSA guidelines

Methodist Hospital develops new technology to rapidly detect drug-resistant TB

CSL Biotherapies receives U.S. Government contract to supply pandemic vaccine antigens

Data from Sangamo BioSciences’ SB-728-T Phase 1 clinical programs on HIV/AIDS

Intermittent hormone therapy effective for prostate cancer patients

Therapeutic targets for pemphigus vulgaris discovered

Reduced NF-κB expression linκed to postradiation oral mucosa vulnerability

Baxter commences anti-MIF antibody Phase I trial in malignant solid tumors

Study sheds new light on why most bone marrow transplant patients suffer acute GVHD

ImmusanT commences Nexvax2 clinical trials for celiac disease in New Zealand, Australia and the U.S.

PRISM technique as accurate as ELISAs in identifying proteins within biological samples

Potassium-channel autoimmunity linked to chronic pain

Sophiris announces data from PRX302 transrectal safety study on Benign Prostatic Hyperplasia

Soligenix’s RiVax induces greater ricin neutralizing antibody levels in humans

Researchers discover new immune response mechanism during infection

Childhood coagulation marker levels distinct from adulthood

Human Vaccines & Immunotherapeutics Special Focus provides critical view on cancer vaccines

Research roundup: Who do patients seek for primary care?; Treating kids with antipsychotics

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News